IRIDEX Corporation (NASDAQ:IRIX – Get Free Report) saw a large drop in short interest in October. As of October 30th, there was short interest totaling 39,421 shares, a drop of 48.3% from the October 15th total of 76,195 shares. Based on an average daily trading volume, of 24,978 shares, the days-to-cover ratio is currently 1.6 days. Approximately 0.2% of the company’s shares are sold short.
Institutional Trading of IRIDEX
Several hedge funds and other institutional investors have recently bought and sold shares of IRIX. Renaissance Technologies LLC increased its stake in shares of IRIDEX by 6.7% in the 1st quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock valued at $401,000 after purchasing an additional 25,067 shares in the last quarter. Weber Capital Management LLC ADV acquired a new stake in IRIDEX in the second quarter valued at approximately $206,616. United Capital Financial Advisors LLC acquired a new stake in IRIDEX in the second quarter valued at approximately $41,000. Diversify Wealth Management LLC acquired a new stake in IRIDEX in the first quarter valued at approximately $35,000. Finally, Diversify Advisory Services LLC purchased a new stake in shares of IRIDEX in the second quarter valued at approximately $30,000. 20.10% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings raised shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, November 3rd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, IRIDEX presently has an average rating of “Hold” and a consensus price target of $3.00.
View Our Latest Research Report on IRIDEX
IRIDEX Trading Down 0.3%
NASDAQ:IRIX traded down $0.00 during midday trading on Monday, reaching $0.69. 84,563 shares of the stock traded hands, compared to its average volume of 27,970. IRIDEX has a 12-month low of $0.61 and a 12-month high of $1.65. The business has a 50-day moving average of $0.71 and a two-hundred day moving average of $1.00.
IRIDEX (NASDAQ:IRIX – Get Free Report) last released its quarterly earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The business had revenue of $12.57 million for the quarter, compared to analyst estimates of $13.59 million. As a group, sell-side analysts anticipate that IRIDEX will post -0.12 earnings per share for the current fiscal year.
IRIDEX Company Profile
IRIDEX Corporation develops, manufactures and markets laser-based medical systems and related delivery devices for eye-care professionals. Its products are used to treat retinal diseases and glaucoma, including through laser procedures designed to preserve or improve vision. The company’s offerings include ophthalmic laser systems such as the Cyclo G6 glaucoma laser system and IQ-series photocoagulators, along with treatment-delivery devices and technologies including MicroPulse laser therapy. IRIDEX was founded in 1989 and serves customers internationally through direct sales and distribution partners.
See Also
- Five stocks we like better than IRIDEX
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.
